Points from CC I just quickly went through today's cc, here are some more points to add to discussions:
average life cycle of a patient 17 months.
currently 40 sales reps, goal in F18 to have 16 new reps (4 new per quarter).
42% growth in F17, will try to get on the same path in F18.
incremental growth opportunities: shared savings program with top 5 payors (in discussion stage with payors that presents an opportunity to grab a big batch of patients).
Diversify from Medicare into paediatric vent patient market for kids through strategic acquisition (benefits: easier to expand the network, better payors).
F17 revenue 46.5MM with EBITDA 11.6MM.
Q/A:
bonus will be evenly spread going forward, annual F17 EBITDA margin represents individual quarter margin going forward.
bad debt, in F17 11% of total revenue (normal indication), target between 9-13%, mostly due to patient being at the end of their life.
goal is to graduate to senior exchange rather sooner than later, possibly cross listed.
on the road in the next few weeks, toronto, montreal, calgary, vancouver